Trumping the Budget blues?
Perhaps the uncertainty of the Union Budget pales before the changes that US President Trump will make as he gets down to business…
Author
India’s biopharma industry needs to become a little bit more ambitious
In a free wheeling conversation with Viveka Roychowdhury, Dr Dhananjay Patankar, biopharma consultant, explains why Indian…
Will Epygen’s biosimilars bets pay off?
Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a…
2025: A year of stricter rules, course corrections?
Will 2025 see a more vigilant government when it comes to violations by pharma companies, be it GMP slip ups or the Uniform Code…
Eco-conscious packaging: A strategic opportunity
Larger pharma companies are applying sustainable practices and eco-conscious materials to packaging and labelling, leading to…
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
ACG Inspection’s Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG…
We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Sanjaya Mariwala, Executive Chairman and MD, OmniActive Health Technologies shares insights into the company’s significant…
30 years and counting …
The pharma industry has breached many barriers, but we have miles to go before we can rest on our laurels
The quest for quality continues
It is considerably more difficult to live up to these professed codes of conduct off stage, as it needs to flow right from the…
Data and digital is a force to reckon with when it comes to India
Suneela Thatte highlighted that while the GCC was initially set up for cost savings in drug development, the focus has shifted to…